KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Amortization of Deferred Charges (2016 - 2021)

Historic Amortization of Deferred Charges for Jazz Pharmaceuticals (JAZZ) over the last 11 years, with Q1 2021 value amounting to $15.7 million.

  • Jazz Pharmaceuticals' Amortization of Deferred Charges rose 3073.33% to $15.7 million in Q1 2021 from the same period last year, while for Mar 2021 it was $60.3 million, marking a year-over-year increase of 2768.34%. This contributed to the annual value of $56.7 million for FY2020, which is 2212.04% up from last year.
  • As of Q1 2021, Jazz Pharmaceuticals' Amortization of Deferred Charges stood at $15.7 million, which was up 3073.33% from $16.0 million recorded in Q4 2020.
  • In the past 5 years, Jazz Pharmaceuticals' Amortization of Deferred Charges ranged from a high of $16.0 million in Q4 2020 and a low of $5.6 million during Q1 2017
  • Its 5-year average for Amortization of Deferred Charges is $11.3 million, with a median of $11.3 million in 2018.
  • Within the past 5 years, the most significant YoY rise in Jazz Pharmaceuticals' Amortization of Deferred Charges was 8908.28% (2018), while the steepest drop was 462.38% (2018).
  • Jazz Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $10.8 million in 2017, then increased by 4.62% to $11.3 million in 2018, then grew by 6.11% to $12.0 million in 2019, then surged by 33.93% to $16.0 million in 2020, then fell by 2.23% to $15.7 million in 2021.
  • Its last three reported values are $15.7 million in Q1 2021, $16.0 million for Q4 2020, and $15.8 million during Q3 2020.